For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
June 24, 2002
- Iressa Recommended for Approval by CDFS Panel
June 24, 2002
- BD: New M. tuberculosis Susceptibility Testing Reagent
June 24, 2002
- Science and Technology White Paper Stresses Importance of Innovation
June 24, 2002
- MBL Gets License from Oncotherapy Science
June 24, 2002
- Precautions against Stevens-Johnson Syndrome Issued Again
June 24, 2002
- DIAGNOSTIC NEWS IN BRIEF
June 24, 2002
- 46 Active Ingredients Listed for Quality Reevaluation
June 24, 2002
- WORLD NEWS
June 24, 2002
- REGULATORY NEWS IN BRIEF
June 24, 2002
- BULLETIN
June 24, 2002
- MPC to Place Top Priority on Independent Marketing in US
June 24, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
June 24, 2002
- Tsumura Forecasts Rapid Recovery of Business
June 24, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
June 24, 2002
- Rohto: Net Profits Down Due to Slump of Eye Care Products
June 17, 2002
- Difficulty Related to Pediatric Emergency Care Revealed: Survey
June 17, 2002
- Spiriva Effects on COPD Reported
June 17, 2002
- Zeria: Sales Down 3.5% to \53.8 Bil.
June 17, 2002
- Quintiles to Conduct Clinical Trials on Japanese in Hawaii
June 17, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…